{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:50:41Z","timestamp":1791867041961,"version":"4.3.4"},"reference-count":104,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007496","name":"Biomedical Laboratory Research and Development, VA Office of Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007496","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24-AR 18 02207"],"award-info":[{"award-number":["K24-AR 18 02207"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006379","name":"Office of Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006379","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dental Clinics of North America"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.cden.2013.07.003","type":"journal-article","created":{"date-parts":[[2013,8,15]],"date-time":"2013-08-15T12:37:55Z","timestamp":1376570275000},"page":"611-630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":140,"title":["Mucous Membrane Pemphigoid"],"prefix":"10.1016","volume":"57","author":[{"given":"Hong-Hui","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesta","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Sollecito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cden.2013.07.003_bib1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/archderm.138.3.370","article-title":"The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators","volume":"138","author":"Chan","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.cden.2013.07.003_bib3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/ICU.0b013e328358bafd","article-title":"Mucous membrane pemphigoid: recent advances","volume":"23","author":"Srikumaran","year":"2012","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.cden.2013.07.003_bib4","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1046\/j.1365-2133.2001.04471.x","article-title":"Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180","volume":"145","author":"Schmidt","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib5","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/1523-1747.ep12876206","article-title":"Studies of cicatricial pemphigoid autoantibodies using direct immunoelectron microscopy and immunoblot analysis","volume":"94","author":"Bernard","year":"1990","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clim.2006.10.007","article-title":"Oral pemphigoid autoantibodies preferentially target BP180 ectodomain","volume":"122","author":"Calabresi","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.cden.2013.07.003_bib7","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1172\/JCI116033","article-title":"Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease","volume":"90","author":"Domloge-Hultsch","year":"1992","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cden.2013.07.003_bib8","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/1523-1747.ep12292578","article-title":"Laminin-6 and laminin-5 are recognized by autoantibodies in a subset of cicatricial pemphigoid","volume":"108","author":"Chan","year":"1997","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib9","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/archderm.135.8.954","article-title":"Mucosal morbidity in patients with epidermolysis bullosa acquisita","volume":"135","author":"Luke","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib10","doi-asserted-by":"crossref","first-page":"14714","DOI":"10.1073\/pnas.93.25.14714","article-title":"Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization","volume":"93","author":"Tyagi","year":"1996","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.cden.2013.07.003_bib11","doi-asserted-by":"crossref","first-page":"11579","DOI":"10.1073\/pnas.88.24.11579","article-title":"Association of DQw7 (DQB1*0301) with ocular cicatricial pemphigoid","volume":"88","author":"Ahmed","year":"1991","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.cden.2013.07.003_bib12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/1523-1747.ep12332352","article-title":"Significantly increased occurrence of HLA-DQB1*0301 allele in patients with ocular cicatricial pemphigoid","volume":"108","author":"Chan","year":"1997","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib13","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1046\/j.1365-2133.2001.04380.x","article-title":"Mucous membrane pemphigoid: HLA-DQB1*0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production","volume":"145","author":"Setterfield","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0738-081X(93)90160-E","article-title":"Drug-induced cicatricial pemphigoid and acquired epidermolysis bullosa","volume":"11","author":"Van Joost","year":"1993","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/0738-081X(93)90164-8","article-title":"Drug-induced blistering oral lesions","volume":"11","author":"Laskaris","year":"1993","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib16","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/eye.2012.119","article-title":"Incidence, presenting features, and diagnosis of cicatrising conjunctivitis in the United Kingdom","volume":"26","author":"Radford","year":"2012","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.cden.2013.07.003_bib17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archderm.1995.01690130050009","article-title":"Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group","volume":"131","author":"Bernard","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib18","first-page":"434","article-title":"Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany","volume":"7","author":"Bertram","year":"2009","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"10.1016\/j.cden.2013.07.003_bib19","series-title":"Burket's oral medicine: diagnosis and treatment","first-page":"67","article-title":"Ulcerative, vesicular, and bullous lesions","author":"Woo","year":"2008"},{"key":"10.1016\/j.cden.2013.07.003_bib20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0190-9622(91)70168-2","article-title":"Cutaneous manifestations of cryoglobulinemia: clinical and histopathologic study of seventy-two patients","volume":"25","author":"Cohen","year":"1991","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2230.1977.tb02570.x","article-title":"Cicatricial pemphigoid in a young girl: report of a case","volume":"2","author":"Jolliffe","year":"1977","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1440-0960.1981.tb00773.x","article-title":"Cicatricial pemphigoid in a four-year-old child: a case report","volume":"22","author":"Rogers","year":"1981","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1525-1470.2009.01079.x","article-title":"Early onset childhood cicatricial pemphigoid: a case report and review of the literature","volume":"27","author":"Kharfi","year":"2010","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.clim.2004.04.010","article-title":"Profile of autoantibody to basement membrane zone proteins in patients with mucous membrane pemphigoid: long-term follow up and influence of therapy","volume":"112","author":"Yeh","year":"2004","journal-title":"Clin Immunol"},{"key":"10.1016\/j.cden.2013.07.003_bib25","first-page":"1302","article-title":"Analysis of antigens targeted by circulating IgG and IgA antibodies in patients with mucous membrane pemphigoid predominantly affecting the oral cavity","volume":"75","author":"Carrozzo","year":"2004","journal-title":"J\u00a0Periodontol"},{"key":"10.1016\/j.cden.2013.07.003_bib26","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/1523-1747.ep12606244","article-title":"Adhesion molecules. II: Interactions of keratinocytes with epidermal basement membrane","volume":"104","author":"Yancey","year":"1995","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib27","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0092-8674(00)00087-8","article-title":"The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B\/MMP-9 in\u00a0vivo","volume":"102","author":"Liu","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.cden.2013.07.003_bib28","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm1496","article-title":"Humanization of autoantigen","volume":"13","author":"Nishie","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.cden.2013.07.003_bib29","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/0030-4220(94)90312-3","article-title":"Immunopathology of oral mucosal ulcerative, desquamative, and bullous diseases. Selective review of the literature","volume":"77","author":"Eversole","year":"1994","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1016\/j.cden.2013.07.003_bib30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1601-0825.1996.tb00221.x","article-title":"Adhesion molecules and oral mucosal diseases","volume":"2","author":"Eversole","year":"1996","journal-title":"Oral Dis"},{"key":"10.1016\/j.cden.2013.07.003_bib31","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1172\/JCI118942","article-title":"Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice","volume":"98","author":"Lazarova","year":"1996","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cden.2013.07.003_bib32","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1046\/j.1523-1747.2000.00829.x","article-title":"Human anti-laminin 5 autoantibodies induce subepidermal blisters in an experimental human skin graft model","volume":"114","author":"Lazarova","year":"2000","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib33","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1177\/00220345010800080601","article-title":"Autoantibodies to human alpha6 integrin in patients with oral pemphigoid","volume":"80","author":"Bhol","year":"2001","journal-title":"J\u00a0Dent Res"},{"key":"10.1016\/j.cden.2013.07.003_bib34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0161-6420(93)31644-1","article-title":"The conjunctiva in acute and chronic mucous membrane pemphigoid. An immunohistochemical analysis","volume":"100","author":"Bernauer","year":"1993","journal-title":"Ophthalmology"},{"key":"10.1016\/j.cden.2013.07.003_bib35","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1076\/ceyr.16.8.820.8987","article-title":"Limbal conjunctival Langerhans cell density in ocular cicatricial pemphigoid: an indirect immunofluorescence study on Dispase-split conjunctiva","volume":"16","author":"Bodaghi","year":"1997","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.cden.2013.07.003_bib36","first-page":"1449","article-title":"T-helper 17 lymphocytes in ocular cicatricial pemphigoid","volume":"15","author":"Lambiase","year":"2009","journal-title":"Mol Vis"},{"key":"10.1016\/j.cden.2013.07.003_bib37","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0738-081X(00)00196-6","article-title":"Mucous membrane pemphigoid","volume":"19","author":"Chan","year":"2001","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ophtha.2003.03.001","article-title":"Mucous membrane pemphigoid and pseudopemphigoid","volume":"111","author":"Thorne","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.cden.2013.07.003_bib39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00003226-199105000-00001","article-title":"Systemic chemotherapy for ocular cicatricial pemphigoid","volume":"10","author":"Tauber","year":"1991","journal-title":"Cornea"},{"key":"10.1016\/j.cden.2013.07.003_bib40","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.det.2011.06.022","article-title":"Therapeutic approaches to patients with mucous membrane pemphigoid","volume":"29","author":"Kourosh","year":"2011","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.cden.2013.07.003_bib41","first-page":"527","article-title":"Cicatricial pemphigoid","volume":"84","author":"Foster","year":"1986","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.cden.2013.07.003_bib42","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/00003226-199209000-00015","article-title":"Improved detection of disease progression in ocular cicatricial pemphigoid","volume":"11","author":"Tauber","year":"1992","journal-title":"Cornea"},{"key":"10.1016\/j.cden.2013.07.003_bib43","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/bjo.2010.188011","article-title":"Validation of a fornix depth measurer: a putative tool for the assessment of progressive cicatrising conjunctivitis","volume":"95","author":"Williams","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.cden.2013.07.003_bib44","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00417-011-1853-z","article-title":"Ocular and oral grading of mucous membrane pemphigoid","volume":"250","author":"Reeves","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.cden.2013.07.003_bib45","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1046\/j.1365-2133.1998.02168.x","article-title":"Mucous membrane pemphigoid: a dual circulating antibody response with IgG and IgA signifies a more severe and persistent disease","volume":"138","author":"Setterfield","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib46","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1038\/sj.jid.5700465","article-title":"Antigen specificity in subsets of mucous membrane pemphigoid","volume":"126","author":"Rashid","year":"2006","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib47","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/archderm.1993.01680250060007","volume":"129","author":"Chan","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib48","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1365-2133.2005.06998.x","article-title":"Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity","volume":"154","author":"Oyama","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib49","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/jama.284.3.350","article-title":"Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations","volume":"284","author":"Yancey","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.cden.2013.07.003_bib50","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2340\/00015555-1142","article-title":"Oral mucous membrane pemphigoid: complete response to topical tacrolimus","volume":"91","author":"Lee","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.cden.2013.07.003_bib51","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1754-4505.2006.tb01512.x","article-title":"Successful treatment of mucous membrane pemphigoid with tacrolimus","volume":"26","author":"Suresh","year":"2006","journal-title":"Spec Care Dentist"},{"key":"10.1016\/j.cden.2013.07.003_bib52","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1365-2230.2004.01619.x","article-title":"Topical tacrolimus for oral cicatricial pemphigoid","volume":"29","author":"Assmann","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib53","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1600-0714.2008.00653.x","article-title":"The management of oral mucous membrane pemphigoid with dapsone and topical corticosteroid","volume":"37","author":"Arash","year":"2008","journal-title":"J\u00a0Oral Pathol Med"},{"key":"10.1016\/j.cden.2013.07.003_bib54","first-page":"201","article-title":"Dapsone therapy of cicatricial pemphigoid","volume":"7","author":"Rogers","year":"1988","journal-title":"Semin Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib55","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1079-2104(99)70110-1","article-title":"A\u00a0retrospective study of the management of oral mucous membrane pemphigoid with dapsone","volume":"88","author":"Ciarrocca","year":"1999","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.cden.2013.07.003_bib56","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cden.2004.07.004","article-title":"Mucous membrane pemphigoid","volume":"49","author":"Sollecito","year":"2005","journal-title":"Dent Clin North Am"},{"key":"10.1016\/j.cden.2013.07.003_bib57","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/archderm.1984.01650480044015","article-title":"Vitamin E and dapsone-induced hemolysis","volume":"120","author":"Kelly","year":"1984","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib58","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2133.1995.tb05022.x","article-title":"Cimetidine improves the therapeutic\/toxic ratio of dapsone in patients on chronic dapsone therapy","volume":"132","author":"Rhodes","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib59","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-4632.2009.04322.x","article-title":"Prevention and treatment of systemic glucocorticoid side effects","volume":"49","author":"Moghadam-Kia","year":"2010","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib60","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1590\/S0482-50042012000400009","article-title":"Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"52","author":"Pereira","year":"2012","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.cden.2013.07.003_bib61","doi-asserted-by":"crossref","first-page":"e477","DOI":"10.1111\/j.1365-2230.2009.03548.x","article-title":"Cyclophosphamide and amniotic membrane transplantation in the management of ocular disease in a case of antiepiligrin cicatricial pemphigoid","volume":"34","author":"Hayashi","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib62","first-page":"101","article-title":"Treatment of cicatricial pemphigoid with pulse intravenous cyclophosphamide","volume":"137","author":"Musette","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib63","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/archderm.1997.03890380119026","article-title":"Cicatricial pemphigoid successfully treated with pulse intravenous cyclophosphamide","volume":"133","author":"Pandya","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib64","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/j.oooo.2012.01.030","article-title":"Treatment of mucous membrane pemphigoid with the combination of mycophenolate mofetil, dapsone, and prednisolone: a case series","volume":"114","author":"Staines","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.cden.2013.07.003_bib65","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3109\/09273948.2011.624288","article-title":"Long-term results of therapy with mycophenolate mofetil in ocular mucous membrane pemphigoid","volume":"19","author":"Doycheva","year":"2011","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.cden.2013.07.003_bib66","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1751-7125.2008.07318.x","article-title":"Coexistent psoriasis and bullous pemphigoid responding to mycophenolate mofetil monotherapy","volume":"7","author":"Rallis","year":"2008","journal-title":"Skinmed"},{"key":"10.1016\/j.cden.2013.07.003_bib67","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1097\/ICO.0b013e3181da580a","article-title":"A\u00a0rare unilateral case of ocular mucous membrane pemphigoid","volume":"29","author":"Roufas","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.cden.2013.07.003_bib68","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","article-title":"Methotrexate for ocular inflammatory diseases","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.cden.2013.07.003_bib69","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ophtha.2003.07.010","article-title":"Methotrexate therapy for ocular cicatricial pemphigoid","volume":"111","author":"McCluskey","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.cden.2013.07.003_bib70","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1157\/13088180","article-title":"Ocular autoimmune pemphigoid and cyclosporin A","volume":"34","author":"Alonso","year":"2006","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.cden.2013.07.003_bib71","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2009.08.010","article-title":"Cyclosporine for ocular inflammatory diseases","volume":"117","author":"Kacmaz","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.cden.2013.07.003_bib72","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1365-4362.1995.tb01095.x","article-title":"Cyclosporine therapy of life-threatening cicatricial pemphigoid affecting the respiratory tract","volume":"34","author":"Williams","year":"1995","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib73","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00160769","article-title":"Long-term results of systemic chemotherapy for ocular cicatricial pemphigoid","volume":"82","author":"Foster","year":"1992","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/j.cden.2013.07.003_bib74","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1601-0825.2012.01919.x","article-title":"Biologics in oral medicine: principles of use and practical considerations","volume":"18","author":"O'Neill","year":"2012","journal-title":"Oral Dis"},{"key":"10.1016\/j.cden.2013.07.003_bib75","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1600-0714.2008.00693.x","article-title":"Off-label use of biologicals in the management of inflammatory oral mucosal disease","volume":"37","author":"O'Neill","year":"2008","journal-title":"J\u00a0Oral Pathol Med"},{"key":"10.1016\/j.cden.2013.07.003_bib76","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/archderm.142.11.1457","article-title":"Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients","volume":"142","author":"Canizares","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib77","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1684\/ejd.2010.0970","article-title":"Coexisting bullous pemphigoid and psoriasis successfully treated with etanercept","volume":"20","author":"Cusano","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib78","first-page":"68","article-title":"Recalcitrant cicatricial pemphigoid treated with the anti-TNF-alpha agent etanercept","volume":"9","author":"Kennedy","year":"2010","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib79","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2340\/00015555-0132","article-title":"Treatment of ocular cicatricial pemphigoid with the tumour necrosis factor alpha antagonist etanercept","volume":"87","author":"Prey","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.cden.2013.07.003_bib80","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1067\/mjd.2001.119100","article-title":"Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept","volume":"46","author":"Sacher","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib81","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1365-4632.2010.04707.x","article-title":"Therapeutic effect of etanercept in anti-laminin 5 (laminin 332) mucous membrane pemphigoid","volume":"50","author":"Schulz","year":"2011","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib82","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/jid.2011.120","article-title":"Generating consensus research goals and treatment strategies for pemphigus and pemphigoid: The 2010 JC Bystryn Pemphigus and Pemphigoid Meeting","volume":"131","author":"Schultz","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib83","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","article-title":"Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report","volume":"117","author":"Foster","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.cden.2013.07.003_bib84","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaad.2012.10.018","article-title":"Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature","volume":"68","author":"Shetty","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib85","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/archdermatol.2011.54","article-title":"Rituximab for patients with refractory mucous membrane pemphigoid","volume":"147","author":"Le Roux-Villet","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib86","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/bjo.2007.129510","article-title":"The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement","volume":"93","author":"Ross","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.cden.2013.07.003_bib87","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/archdermatol.2011.167","article-title":"Rituximab for severe mucous membrane pemphigoid: safe enough to be drug of first choice?","volume":"147","author":"Hertl","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib88","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","article-title":"Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients","volume":"65","author":"Kasperkiewicz","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib89","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2340\/00015555-0560","article-title":"Successful treatment of mucous membrane pemphigoid with the anti-CD-20 antibody rituximab","volume":"89","author":"Schumann","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.cden.2013.07.003_bib90","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1365-2133.1995.tb00727.x","article-title":"Minimizing cicatricial pemphigoid orodynia with minocycline","volume":"132","author":"Poskitt","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib91","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1046\/j.1365-2230.1998.00379.x","article-title":"Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy","volume":"23","author":"Reiche","year":"1998","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib92","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/archotol.128.12.1420","article-title":"Antiepiligrin cicatricial pemphigoid of the larynx successfully treated with a combination of tetracycline and niacinamide","volume":"128","author":"Sakamoto","year":"2002","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.cden.2013.07.003_bib93","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ophtha.2007.10.029","article-title":"Intravenous immunoglobulins and mucous membrane pemphigoid","volume":"115","author":"Mignogna","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.cden.2013.07.003_bib94","first-page":"1226","article-title":"Low-level laser therapy in the\u00a0treatment of mucous membrane pemphigoid: a promising procedure","volume":"81","author":"Yilmaz","year":"2010","journal-title":"J\u00a0Periodontol"},{"key":"10.1016\/j.cden.2013.07.003_bib95","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/01.ico.0000127483.08466.56","article-title":"Ocular cicatricial pemphigoid, keratomycosis, and intravenous immunoglobulin therapy","volume":"23","author":"Iaccheri","year":"2004","journal-title":"Cornea"},{"key":"10.1016\/j.cden.2013.07.003_bib96","first-page":"222","article-title":"Multiple mucosal involvement in cicatricial pemphigoid","volume":"29","author":"Trimarchi","year":"2009","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"10.1016\/j.cden.2013.07.003_bib97","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/lary.20763","article-title":"Laryngeal mucous membrane pemphigoid: a systematic review and pooled-data analysis","volume":"120","author":"Higgins","year":"2010","journal-title":"Laryngoscope"},{"key":"10.1016\/j.cden.2013.07.003_bib98","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2012.07.053","article-title":"Visual improvement after cultivated oral mucosal epithelial transplantation","volume":"120","author":"Sotozono","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.cden.2013.07.003_bib99","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s10103-012-1137-9","article-title":"Low-level laser therapy for oral mucous membrane pemphigoid","volume":"27","author":"Cafaro","year":"2012","journal-title":"Lasers Med Sci"},{"key":"10.1016\/j.cden.2013.07.003_bib100","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3928\/15428877-20091030-11","article-title":"Transscleral diode laser cyclophotocoagulation in a patient with ocular cicatricial pemphigoid","volume":"40","author":"Moore","year":"2009","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.cden.2013.07.003_bib101","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1001\/archderm.1995.01690170082012","article-title":"Localized cicatricial pemphigoid of the Brunsting-Perry type with transition into disseminated cicatricial pemphigoid. Report of a case proved by preembedding immunogold electron microscopy","volume":"131","author":"Kurzhals","year":"1995","journal-title":"Arch Dermatol"},{"issue":"Suppl","key":"10.1016\/j.cden.2013.07.003_bib102","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1007\/BF00585917","article-title":"Vegetating cicatricial pemphigoid. A new subset of the cicatricial pemphigoid spectrum","volume":"279","author":"Wolff","year":"1987","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.cden.2013.07.003_bib103","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jaad.2010.10.028","article-title":"Cicatricial pemphigoid of the scalp mimicking discoid lupus erythematosus","volume":"65","author":"Das","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cden.2013.07.003_bib104","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s003470050021","article-title":"Ocular cicatricial pemphigoid. Retrospective analysis of risk factors and complications","volume":"97","author":"Messmer","year":"2000","journal-title":"Ophthalmologe"}],"container-title":["Dental Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011853213000542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011853213000542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T22:28:39Z","timestamp":1762122519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011853213000542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":104,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0011853213000542"],"URL":"https:\/\/doi.org\/10.1016\/j.cden.2013.07.003","relation":{},"ISSN":["0011-8532"],"issn-type":[{"value":"0011-8532","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mucous Membrane Pemphigoid","name":"articletitle","label":"Article Title"},{"value":"Dental Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cden.2013.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}